The company has developed over 20 algorithms for a range of conditions including cancer, Alzheimer’s, osteoarthritis and liver disease.
It has recently launched chest X-ray and CT scan products for COVID-19, to support early detection through imaging biomarkers. Its products are used in over 70 hospitals and 11 clinical trials across the world, and has processed 6.5 million images to date.
With the investment the company plans to expand its range of algorithms and components available through its AI-based radiology platform.
Angel Alberich Bayarri, founder and CEO of QUIBIM, said: “QUIBIM is now at a scale-up point ready to grow internationally while maintaining great science at the core of our mission.”
“This latest round of funding will be used to boost the AI platform, our available algorithms and high-value components, to provide a seamless, all-in-one solution supporting healthcare providers.”
“Our new investors will open opportunities for us in new markets and help us to strengthen our brand internationally. We will be able to promote our new prostate, musculoskeletal and oncology solutions and increase sales globally, by expanding our workforce over the coming year.”
Rocio Pillado, partner at Adara Ventures, said: “We are excited by the potential of radiomics to improve disease detection and enable precision treatments guided by imaging biomarkers.”
Related
- £126 million in funding for DHSC's "biggest investment into…
- Draft budget 2025/26 for Wales: £600m "extra revenue and…
- Newcastle Upon Tyne Hospitals' partnership sees £2.56…
- 87 acute hospital trusts and 28 ICBs sign up to Federated…
- Children's health platform Little Journey raises £6 million…
- Barts Health deploys Cynerio's cyber security platform…
